Brief: LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
11/11/2024 21:44
Nov 11 (Reuters) - LivaNova PLC LIVN.O :
* LIVANOVA ANNOUNCES OSPREY CLINICAL STUDY MEETS PRIMARY
SAFETY
AND EFFICACY ENDPOINTS
* LIVANOVA PLC - NO SERIOUS ADVERSE DEVICE-RELATED OR
PROCEDURE-RELATED EVENTS REPORTED
Source text: ID:nBw93ZXqHa
Further company coverage: LIVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Livanova
See all newsAIM - Schedule One Update - TEK 4 Holdco Limited
Competition and Mkts - Merger Update: NRG Fleet / Specialist Fleet
LivaNova PLC reports results for the quarter ended June 30 - Earnings Summary
UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook
Brief: Livanova Demonstrates 84.5% Cumulative Response Rate With Polysync Programming In OSPREY Study